CLINICAL_TRIALS
trial_result
· 2020-08-25
Clinical Trial Update: An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine [Phase 3]
Summary
Open-label, long-term safety study of lasmiditan for acute treatment of migraine completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Eli Lilly and Company | Conditions: Migraine Disorders | Phase 3 | Status: COMPLETED | Results posted: 2020-08-25